Global Cystinuria Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032

Global Cystinuria Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032

Global Cystinuria Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 – 2032

Global Cystinuria Market was valued at US $110.5 Million in 2022 and is expected to reach ~US $200 Million by 2032, growing at a CAGR of 6.1% during the forecast period 2023-2032.

A uncommon hereditary condition called cystinuria causes the amount of cystine to accumulate in the urine. Kidney stones that recur as a result of this develop. Cysteinuria, often referred to as cystine-lysine-arginine-ornithinuria, is brought on by mutations in the SLC3A1 and SLC7A9 genes. Cysteine typically passes via the kidneys, dissolves, and is then reabsorbed into the bloodstream. On the other hand, a genetic abnormality in cystinuria patients interferes with this normal process. As a result, cystine builds up in the urine, which causes crystalline or stone-like formations. Because SLC3A1 and SLC7A9 gene variants are becoming more common, the worldwide cystinuria market is expected to grow at a stable rate. Due to these changes, the number of cases with cystinuria has increased, which causes aberrant cystine transport in the kidneys. With an estimated 1 in 7,000 cases worldwide, cystinuria is the most frequent hereditary cause of kidney stone disease. Some nations, such Sweden, Japan, Australia, Israel, the United Kingdom, and Spain, have prevalence rates that range from one per 100,000 to one per 2,000 people.

Numerous reasons are driving the market's expansion. These include raising knowledge of various treatment choices and boosting the number of special designations awarded by regulatory bodies. In addition, there has been a discernible rise in the cost of developing healthcare infrastructure, an increase in the incidence of hereditary illnesses, and a growing trend in the use of internet pharmacies for prescription drug purchases. A rise in the frequency of strategic alliances between market participants also helps the market. Furthermore, even if indirectly, the sector is anticipated to see rich growth prospects as a result of the expanding personal disposable income.

Numerous firms and organisations have developed and investigated a range of products for their possible therapeutic use in cystinuria as a result of extensive research undertaken over the years. The market for cystinuria treatments is expanding as a result of this continued research and development. One noteworthy clinical trial, co-led by Drs. Chi and Stoller and funded by the FDA and NIH, focusses on treating cystinuria patients with lipoid acid and evaluates the impact on their blood, urine, and kidney stones. A randomised, double-masked, placebo-controlled trial is how the study is set up.

In addition, the possibility of potentially fatal renal diseases in the event that cystinuria is not treated accelerates the market's revenue growth. Furthermore, during the projected period, the high risk of cystinuria recurrence following surgical procedures supports market expansion.

Elevated levels of undissolved cystine and associated amino acids such as arginine, lysine, and ornithine in the urine are indicative of cystinuria, a hereditary metabolic disorder. Urinary tract, bladder, and kidney crystals and stones (calculi) can develop from an excess of cystine in the urine. Renal colic, a condition marked by extreme discomfort in the lower back or side of the abdomen, is frequently one of the initial signs. Urinary tract infections, urinary tract blockages, and haematuria are further possible symptoms. Chronic cystinuria can eventually cause damage to the kidneys.

“Tiopronin segment, by treatment type, to be largest market from 2023 to 2030.”

The segmentation analysis of the treatment type segment is as Captopril, Tiopronin, Penicillamine and Others. Within the pharmaceuticals section, the tiopronin category emerged as the market leader in 2022 and is predicted to maintain its dominance for the duration of the forecast period. The expansion of cystinuria treatment across the globe is credited with this ongoing leadership. Tiopronin is an essential thiol medicine used to treat severe homozygous cystinuria. Individuals who have cystinuria are more likely to develop kidney stones because they typically excrete large levels of cystine in their urine. Over the course of the projection period, the penicillamine sector is expected to hold a sizable market share. Penicillamine is a first-generation chelating agent that forms a soluble disulphide complex with cystine. This procedure may dissolve cystine stones that already exist in addition to aiding in the prevention of new stone formation. The U.S. FDA approved Penicillamine Capsules USP 250 mg in May 2019 for Amerigen Pharmaceuticals Limited.

“Retail pharmacies segment, by end user, to be largest market from 2023 to 2030.”

The segment segmentation analysis of the end users is as hospitals, online pharmacies, retail pharmacies and others. Retail pharmacies accounted for the highest share of the worldwide cystinuria treatment market in 2022. However, between 2023 and 2032, the online pharmacy market is expected to increase rapidly. This increase is explained by customers' growing inclination to purchase prescription drugs from online pharmacies and their steady adoption of this channel of distribution.

“North America to be largest region in Cystinuria Market.”

By region, the market is divided into North America, Europe, APAC, and Others. Others are further divided into the Middle East and South America.

Diseases are thought to affect one in every 7,000 people in the United States, according to the National Organisation for Rare Disease. To this domination also contribute attempts to increase illness awareness among the local community. During the forecast period, the global market for cystinuria disease therapeutics is anticipated to experience revenue growth due to a number of factors, including a rise in kidney stone patients, higher healthcare costs, technological advancements, innovative product development, and obtaining FDA approvals for a variety of product portfolios. The market for cystinuria therapies is expanding in North America due to a number of important factors, such as a rise in the number of cystinuria cases, a rise in the use and knowledge of cystinuria treatments and procedures, and continuous technological improvements. Cystinuria accounts for about 1 percent of all instances of renal stones, affecting approximately 1 in 15,000 individuals in the United States, of which 1 in 170 are heterozygote carriers.

On the other hand, the Asia Pacific area is anticipated to grow at the fastest rate because to increased demand for early diagnosis and technical advancements as well as government initiatives and support financing. This region's developing countries, like South Korea, China, and India, place a high priority on R&D activities and the development of innovative products. In addition, healthcare reforms, such as programs to improve healthcare accessibility, affordability, and quality, are expected to fuel market expansion in these nations. Changes being made to enhance healthcare systems in nations like China and India serve as an example of this.

Cystinuria Competitive Landscape

The competitive landscape of the Cystinuria Market involves assessing the competitive landscape to understand the strengths, weaknesses, opportunities, and threats of the industry. Key industry players have recognized that the adoption of Cystinuria technology holds the potential for further growth. The growing desire among producers to optimize their production costs has spurred collaborative efforts among companies to scale up their production capacity. This strategic collaboration not only aims to increase revenue but also seeks to establish dominance in the market.

The Cystinuria Market is highly competitive, with numerous companies vying for market share. Prominent companies in the Cystinuria Market include:

Major Players:

Travere Therapeutics, Inc.

Dr Reddy's Laboratories Ltd.

Advicenne

Teva Pharmaceutical Industries Ltd.

ANI Pharmaceuticals, Inc.

Viatris Inc.

AdvaCare Pharma

Camber Pharmaceuticals, Inc.

Bausch Health Companies Inc.

Panacea Biotec

Recent Developments:

November 28, 2022: A legally binding agreement has been reached by Lupin Limited, an established pharmaceutical business, to purchase full rights to nine medications from BL Indstria tica Ltd., a part of Bausch Health Companies Inc. Through its wholly-owned Brazilian subsidiary, MedQumica Indstria Farmacêutica.

On May 17, 2021, the first generic version of THIOLA (tiopronin) tablets was introduced in the United States by Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. When used in conjunction with increased fluid intake, alkali, or dietary changes, these pills are meant to help adults and paediatric patients over 9 years old with severe homozygous cystinuria—who do not react well to these treatments alone—avoid the development of cystine kidney stones.

The FDA (United States Food and Drug Administration) approved Penicillamine Tablets USP, 250 mg, which Lupin Limited, a major player in the pharmaceutical sector, released on March 2, 2021. These tablets treat substantial, active rheumatoid arthritis after other drugs have failed. They are the generic version of Mylan Speciality, L.P.'s Depen Tablets, 250 mg. They are also used to treat illnesses including cystinuria and Wilson's disease.